ADMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ADMA Biologics Inc is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is surrounded by significant negative sentiment, allegations of financial misconduct, and declining analyst confidence. The technical indicators are bearish, and there are no strong proprietary trading signals to suggest a short-term opportunity. Additionally, the company's financial performance shows declining net income and EPS, which further weakens its investment appeal.
The MACD is below 0 and negatively contracting, indicating bearish momentum. The RSI is neutral at 45.967, showing no clear trend. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Key support and resistance levels indicate resistance at 9.987 and support at 7.741. Overall, the technical setup is weak.
Hedge funds are buying, with a 719.51% increase in buying activity over the last quarter. Gross margin increased by 18.42% YoY in Q4 2025.
Multiple investigations into allegations of financial misconduct and channel stuffing. Stock price dropped 29% over two trading days following these allegations. Analysts downgraded the stock due to lack of clarity and concerns about financial practices. Insider trading activity is neutral, with no significant trends.
In Q4 2025, revenue increased by 18.39% YoY to $139.16M. However, net income dropped by 55.87% YoY to $49.38M, and EPS fell by 55.56% YoY to 0.2. While gross margin improved to 63.78%, the significant decline in profitability metrics raises concerns.
Analysts have downgraded the stock to Neutral from Overweight, citing concerns about financial practices and lack of transparency. No price target is currently available.
